Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2000 Jul 20;99(3):309–314. doi: 10.1016/S0002-9343(99)80164-8

Myocarditis and idiopathic dilated cardiomyopathy

Charles A Brown 1, John B O'Connell 1,∗
PMCID: PMC7119456  PMID: 7653492

Abstract

Idiopathic dilated cardiomyopathy (IDC) accounts for 25% of cases of heart failure in the United States. Understanding the relationship between an inciting event or agent and the development of IDC has progressed only recently. Once IDC has developed, treatment is palliative and little can be done to alter the natural course of the disease. Active myocarditis, a suspected precursor of IDC, is myocardial inflammation and injury without ischemia. The disease ranges from a self-limited flulike illness to one of serious consequence with arrhythmias, heart failure, or death. Many agents have been associated with myocarditis, and the clinical manifestations depend on an interplay between the inciting agent and the host response. The development of a murine model and the expanded use of endomyocardial biopsy using the Dallas criteria have increased our understanding of myocarditis and its sequelae. Therapy consists of managing symptoms using conventional medical regimens for heart failure. Immunosuppressive therapy should be reserved for patients with biopsy-proven disease who have failed conventional therapy. Continued deterioration warrants ventricular assistance and consideration of cardiac transplantation.

References

  • 1.O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994;13:S107–S112. (suppl) [PubMed] [Google Scholar]
  • 2.Sole MJ, Liu P. Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol. 1993;22(suppl A):99A–105A. doi: 10.1016/0735-1097(93)90470-l. [DOI] [PubMed] [Google Scholar]
  • 3.Aretz HT, Billingham ME, Edwards WD. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol. 1986;1:3–14. [PubMed] [Google Scholar]
  • 4.Olinde KD, O'Connell JB. Inflammatory heart disease: pathogenesis, clinical manifestation, and treatment of myocarditis. Annu Rev Med. 1994;45:48–50. doi: 10.1146/annurev.med.45.1.481. [DOI] [PubMed] [Google Scholar]
  • 5.Woodruff JF. Viral myocarditis. Am J Pathol. 1980;101:427–479. [PMC free article] [PubMed] [Google Scholar]
  • 6.Reyes MP, Ho K-L, Smith F. A mouse model of dilated-type cardiomyopathy due to coxsackie virus B3. J Infect Dis. 1981;144:232–236. doi: 10.1093/infdis/144.3.232. [DOI] [PubMed] [Google Scholar]
  • 7.Woodruff JF, Woodruff JJ. Involvement of T lymphocyte in pathogenesis of Coxsackie virus B3 heart disease. J Immunol. 1974;113:1726–1734. [PubMed] [Google Scholar]
  • 8.Paque RE, Straus DC, Mealon TJ, Gauntt CJ. Fractionation and immunologic assessment of KCl extracted cardiac antigens in coxsackie virus B3 virus induced myocarditis. J Immunol. 1979;123:358–364. [PubMed] [Google Scholar]
  • 9.Limas CJ, Goldenberg IF, Limas C. Auto-antibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. Circulation. 1989;64:97–103. doi: 10.1161/01.res.64.1.97. [DOI] [PubMed] [Google Scholar]
  • 10.Neu N, Craig SW, Rose NR. Coxsackie virus induced myocarditis in mice: cardiac myosin auto-antibodies do not cross-react with the virus. Clin Exp Immunol. 1987;69:566–574. [PMC free article] [PubMed] [Google Scholar]
  • 11.Schultheiss HP. The significance of auto-antibodies against ADPATP carrier for the pathogenesis of myocarditis and dilated cardiomyopathy—clinical and experimental data. Springer Semin Immunopathol. 1989;11:15–30. doi: 10.1007/BF00197081. [DOI] [PubMed] [Google Scholar]
  • 12.Tracy S, Wiegand V, McManus B. Molecular approaches to enteroviral diagnosis in idiopathic cardiomyopathy and myocarditis. J Am Coll Cardiol. 1990;15:1688–1694. doi: 10.1016/0735-1097(90)92846-t. [DOI] [PubMed] [Google Scholar]
  • 13.Fletcher GF, Coleman MT, Feorino PM. Viral antibodies in patients with primary myocardial disease. Am J Cardiol. 1968;21:6–10. doi: 10.1016/0002-9149(68)90006-4. [DOI] [PubMed] [Google Scholar]
  • 14.Cambridge G, MacArthur CGC, Waterson AP. Antibodies to coxsackie B viruses in congestive cardiomyopathy. Br Heart J. 1979;41:692–696. doi: 10.1136/hrt.41.6.692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kitaura Y. Virological study of idiopathic cardiomyopathy. Serological study of virus antibodies and immunofluorescent study of myocardial biopsies. Jpn Circ J. 1981;41:279–294. doi: 10.1253/jcj.45.279. [DOI] [PubMed] [Google Scholar]
  • 16.Bowles N, Richardson P, Olsen E, ARchard L. Detection of coxsackie B virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet. 1986;1:1120–1123. doi: 10.1016/s0140-6736(86)91837-4. [DOI] [PubMed] [Google Scholar]
  • 17.Archard L, Bowles N, Olsen E, Richardson C. Detection of persistent coxsackie B virus RNA in dilated myocarditis and myocarditis. Eur Heart J. 1987;8:437–440. (suppl) [Google Scholar]
  • 18.Wynne J, Braunwald E. The cardiomyopathies and myocarditides: toxic, chemical and physical damage to the heart. In: Braunwald E, editor. Heart Disease: A Textbook of Cardiovascular Medicine. WB Saunders; Philadelphia: 1992. pp. 1425–1439. [Google Scholar]
  • 19.Myocarditis Treatment Trial (MTT) Investigators 1991 Incidence and clinical characteristics of myocarditis. Circulation. 1991;84(suppl II):II2. Abstract. [Google Scholar]
  • 20.O'Connell JB, Renlund DG. Myocarditis and specific myocardial diseases. In: Schlant RC, Alexander RW, editors. The Heart: Arteries and Veins. 8th ed. McGraw-Hill; New York: 1994. pp. 1591–1607. [Google Scholar]
  • 21.Costanzo-Nordin MR, O'Connell JB, Subramanian R. Myocarditis confirmed by biopsy presenting as acute myocardial infarction. Br Heart J. 1985;53:25–29. doi: 10.1136/hrt.53.1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.O'Connell JB. Immunosuppression for dilated cardiomyopathy. NEJM. 1989;321:1119–1121. doi: 10.1056/NEJM198910193211609. [DOI] [PubMed] [Google Scholar]
  • 23.The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. NEJM. 1987;316:1429–1435. doi: 10.1056/NEJM198706043162301. [DOI] [PubMed] [Google Scholar]
  • 24.The SOLVD Investigators Effect of enalapril on survival of patients with reduced left ventricular ejection fractions and congestive heart failure. NEJM. 1991;325:293–302. doi: 10.1056/NEJM199108013250501. [DOI] [PubMed] [Google Scholar]
  • 25.Cohn JN, Archibald DG, Ziesche S. Effect of vasodilator therapy on mortality in chronic congestive heart failure. NEJM. 1986;314:1547–1552. doi: 10.1056/NEJM198606123142404. [DOI] [PubMed] [Google Scholar]
  • 26.Cohn JN, Johnson G, Ziesche S. A comparison of enalapril with hydralazine-isorbide dinitrate in the treatment of chronic congestive heart failure. NEJM. 1991;325:303–310. doi: 10.1056/NEJM199108013250502. [DOI] [PubMed] [Google Scholar]
  • 27.Vignola PA, Aonuma K, Swaye PS. Lymphocytic myocarditis presenting as unexplained ventricular arrhythmias: diagnosis with endomyo-cardial biopsy and response to immunosuppression. J Am Coll Cardiol. 1984;4:812–819. doi: 10.1016/s0735-1097(84)80411-8. [DOI] [PubMed] [Google Scholar]
  • 28.O'Connell JB, Mason JW. Inflammatory heart disease. In: Hosenpud J, Greenberg B, editors. Congestive Heart Failure: Pathophysiology, Diagnosis and Comprehensive Approach to Management. Springer-Verlag; New York: 1994. pp. 223–233. [Google Scholar]
  • 29.Dembitsky WP, Moore CH, Holman WL. Successful mechanical circulatory support for noncoronary shock. J Heart Lung Transplant. 1992;11:129–135. [PubMed] [Google Scholar]
  • 30.O'Connell JB, Dec GW, Goldenberg IF. Results of heart transplantation for active lymphocytic myocarditis. J Heart Transplant. 1990;9:351–356. [PubMed] [Google Scholar]
  • 31.O'Connell JB, Mason JW. Therapeutic implication of immune mechanism in myocarditis. Springer Semin Immunopathol. 1989;11:43–49. doi: 10.1007/BF00197083. [DOI] [PubMed] [Google Scholar]
  • 32.Mason JW, O'Connell JB, Herskowitz A. A clinical trial of immunosuppression therapy for myocarditis. NEJM. 1995;333:269–275. doi: 10.1056/NEJM199508033330501. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Medicine are provided here courtesy of Elsevier

RESOURCES